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Background. Through improved understanding of the structure-activity relationship attributes of fluoroquinolones, molecule 
development has improved efficacy, safety, and tolerability of the class. Adverse events (AEs) associated with the fluoroquinolones 
are well defined and a prospective part of the development process. However, not all fluoroquinolones have the same AE profile 
with different substitutions on the core molecule resulting in differences in side effects and spectrum of activity. Unique structural 
attributes of delafloxacin (DLX) may differentiate its AE profile compared to other fluoroquinolones. This analysis compared the in-
cidence of AEs between DLX and vancomycin/aztreonam across two phase 3 ABSSSI studies in order to provide a broader overview 
of DLX safety.
Methods. Safety events occurring in all subjects in the pivotal phase 3 trials were pooled to provide a broad overview of DLX 
safety.
Results. DLX was safe and well-tolerated in the pooled phase 3 ABSSSI trial population of 741 subjects. Treatment-emergent 
AEs (TEAEs) were seen in the DLX group versus the comparator group at 45.1% and 47.7%, respectively. Most were mild or mod-
erate in severity. Treatment-related TEAEs were reported in the DLX group versus the comparator group at rates of 22.1% and 26.1%, 
respectively.
Conclusions. Available data show DLX is well tolerated in both intravenous and oral formulation for the treatment of ABSSSI 
and does not appear to be associated with increased risk of AEs associated with other fluoroquinolones. It remains important to 
monitor for potential AEs that have been observed with other fluoroquinolones.
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The quinolones have been one of the most widely administered 
class of antibiotics over the last 30  years and have been used 
to treat approximately 20 billion patients worldwide. Although 
fluoroquinolones (FQs) are generally well tolerated, they have 
certain class side effects, which have been documented.
Reporting of adverse events (AEs) can vary in clinical studies 
on the basis of time of approval, evolving knowledge of tox-
icity, and improved diagnostic capabilities. Clinician awareness 
of potential AEs also plays a part in the clinical setting. In the 
case of FQs, the class effects have been accounted for in reports 
of clinical experience, Food and Drug Administration (FDA) 
advisories, regulatory documents, and clinical studies. Through 
improved understanding of the structure-activity relationship 
(SAR) attributes of FQs, molecule development has been 
directed to improving the efficacy, safety, and tolerability of FQs 
[1–3].
Delafloxacin has recently been approved in the United States 
for the treatment of adult patients with acute bacterial skin 
and skin structure infections (ABSSSIs). The benefits of SAR 
extend to the potency of delafloxacin relative to other FQs 
against Gram-positive bacteria, including methicillin resistant 
Staphylococcus aureus, as well as enhanced potency at acidic 
pH. Further, the unique structural attributes of delafloxacin 
may be associated with a differentiated AE profile compared to 
other FQs [1, 2].
Delafloxacin has been evaluated in 30 phase 1, 2, and 3 clin-
ical trials that included a total of 2658 delafloxacin-treated sub-
jects. Collectively, these trials provide evidence for the favorable 
safety profile and effectiveness of the intravenous (IV) and oral 
formulations of delafloxacin at 300-mg IV and 450-mg oral 
tablet. The phase 2 and phase 3 ABSSSI safety database includes 
1840 patients, of which 868 received multiple doses of delaflox-
acin 300 mg IV/450 mg oral in 4 completed phase 2 and phase 
3 studies. Table 1 All 4 studies used the intended marketed dose 
of delafloxacin of 300 mg IV Q12h. Study 303 [4] included the 
delafloxacin 450-mg oral dose for oral step-down therapy.
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Safety data were collected from the 348 subjects who com-
prised the safety population in the two phase 2 clinical trials 
[5, 6]. Based upon gastrointestinal events seen in the phase 2 
studies, the 300 mg IV Q12h dose was chosen for further devel-
opment. These phase 2 studies were reported elsewhere and due 
to differences in comparators and trial design, the focus of this 
analysis will be based on pooled data from the two phase 3 trials 
that were of similar design and used identical comparators [4, 7]. 
Safety events occurring in all subjects in the pivotal phase 3 trials 
were pooled to provide a broader overview of delafloxacin safety.
METHODS
The results from the two phase 3 trials with over 1500 subjects 
established delafloxacin’s noninferiority to the comparator van-
comycin ± aztreonam in the treatment of adults with ABSSSIs. 
In these studies, adult patients with ABSSSI were randomized 
1:1 to receive delafloxacin monotherapy or vancomycin plus 
aztreonam. Patients received between 5 and 14 days of delaflox-
acin 300 mg IV every 12 hours in study 302 [7] or delafloxacin 
300 mg IV every 12 hours for 3 days with a mandatory blinded 
switch to delafloxacin 450  mg orally every 12 hours in study 
303. Vancomycin was dosed 15  mg/kg IV based upon actual 
body weight with aztreonam 1–2 g every 12 hours. The safety 
analysis population consisted of all enrolled subjects who re-
ceived at least 1 dose of study drug. Of the 741 subjects random-
ized to the delafloxacin arm, 324 subjects were from study 302 
and 417 subjects from study 303. The safety outcomes in IV and 
oral delafloxacin in study 303 are pooled because the 450-mg 
oral dose of delafloxacin has comparable total systemic expo-
sure (area under the curve [AUC]) to the 300-mg IV dose [4].
Safety was assessed by collection of AE reports, clinical lab-
oratory tests, physical examinations, vital sign measurements, 
and 12-lead electrocardiograms (ECGs) at baseline and as clin-
ically indicated thereafter. In study 302, blood samples for in-
tensive blood glucose analysis were obtained on day 3 (± 1 day) 
within 2 hours before the first study drug administration, and 
at 1, 2, 3, 5, and 12 hours after the start of the first infusion (± 
10-minute window after a minimum of 3 consecutive doses of 
study drug). Treatment-emergent AEs (TEAEs) were defined as 
events that occurred or worsened following administration of 
the first dose of the study drug through the 30-day telephone 
follow-up. The investigator assessed the “relatedness” of the 
event to the treatments. These events were coded using the 
Medical Dictionary for Regulatory Activities (MedDRA) 16.1, 
which allows standardization in classification and coding into 
organ classes. AE reports potentially related to the AEs of spe-
cial interest (AESIs) were identified by the use of Standardized 
MedDRA queries (SMQS) where possible. SMQs are validated, 
standard sets of MedDRA terms used to support signal detec-
tion and evaluation of safety topics of interest, casting a wide 
net over multiple AE terms potentially associated with a specific 
medical event of interest.
Table 1. Description of Phase 2 and Phase 3 Clinical Acute Bacterial Skin and Skin Structure Infection Studies
Study Number Title






RX-3341-201[5] A Randomized, double-blind, multicenter study of the 
safety and efficacy of RX-3341 compared with tigecycline 
for the treatment of complicated skin and skin structure 
infections
49 50 Delafloxacin: 300 or 450 mg BID IV 
tigecycline: 100 loading and 50 mg BID 
IV (Multiple dose: 5–14 d)
RX-3341-202[6] A phase 2 exploratory study of objective endpoints in sub-
jects with acute bacterial skin and skin structure infections 
treated with delafloxacin, vancomycin, or linezolid
78 171 Delafloxacin: 300 mg BID IV vancomycin: 
15 mg/kg BID or local standard of care 
linezolid 600 mg BID IV (with concom-
itant aztreonam in linezolid and vanco-
mycin subjects)
(Multiple dose: 5–14 d)
RX-3341-302[7] Phase 3, multicenter, randomized, double-blind, active-con-
trolled study to evaluate the efficacy and safety of delaflox-
acin compared with vancomycin + aztreonam in patients 
with acute bacterial skin and skin structure infections
324 326 Delafloxacin: 300 mg IV in a 1-hour infu-
sion every 12 hrs. Vancomycin: 15 mg/kg 
every 12 hrs (with concomitant aztreo-
nam) (Multiple dose: 5–14 d)
RX-3341-303[4] Phase 3, multicenter, randomized, double-blind, active-con-
trolled study to evaluate the efficacy and safety of IV and 
oral delafloxacin compared with vancomycin + aztreonam 
in patients with acute bacterial skin and skin structure 
infections
417 425 Delafloxacin: 300 mg IV in a 1-hour 
infusion every 12 hrs for 6 doses then 
450 mg oral every 12 hrs. Vancomycin: 
15 mg/kg every 12 hrs or local standard 
of care (with concomitant aztreonam) 
(Multiple dose: 5–14 d)
RX-3341-201 also enrolled 51 patients who received 450 mg IV Q12h delafloxacin for 5 to 14 days; the data for these patients at the 450-mg IV Q12h dose are not included in the pooled 
multiple dose analysis set because the 450-mg IV dose provides higher exposure than planned with the marketed 300-mg IV dose.
Abbreviations: BID, two times a day; IV, intravenous.
aSubjects had to receive at least 1 dose in a treatment.
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RESULTS
The pooled phase 3 analysis set included 741 subjects treated 
with delafloxacin and 751 treated with vancomycin/aztreo-
nam. Patient medical history and demographics were similar 
between the delafloxacin and comparator groups. (Table 2) 
Patients ranged from 18 to 94  years of age with a mean of 
49.0 years in the delafloxacin group and a mean of 48.0 years 
in the comparator group. In both treatment groups, approx-
imately 11% of patients had diabetes and 16% baseline renal 
impairment. A body mass index (BMI) ≥30 kg/m2 was seen 
in 44.1% of delafloxacin patients and 40.7% in the com-
parator. Patients with a history of hepatitis B or C made up 
29.1% and 28.9% of the delafloxacin and comparator groups, 
respectively.
Overall, 13.4% of patients treated with delafloxacin withdrew 
from the studies compared with 14.9% of patients treated with 
vancomycin/aztreonam. The most common reason for with-
drawal from study was patients lost to follow-up (6.6% in the 
delafloxacin group and 7.3% vancomycin/aztreonam). Overall, 
1.5% of patients treated with delafloxacin withdrew from study 
due to an AE compared with 2.8% of patients treated with 
comparators.
Delafloxacin exposure ranged from 0.5 to 14.0 days, with a 
mean of 6.8 days. Most patients (59.2%) received 11 to 28 doses 
of delafloxacin, with 40.7% receiving ≤ 10 doses. There were no 
notable differences between delafloxacin and the comparators 
with regard to exposure (Table 3).
Delafloxacin was safe and well tolerated in the pooled phase 
3 ABSSSI trial population of 741 subjects (Table 4). TEAEs were 
reported in the delafloxacin group versus the comparator group 
at rates of 45.1% and 47.7%, respectively. Most TEAEs were 
mild or moderate in severity, with < 4% of patients in either 
group experiencing severe TEAEs. Similarly, treatment-related 
TEAEs in the delafloxacin group versus the comparator group 
were seen in 22.1% and 26.1% of patients, respectively. Related 
TEAEs leading to premature study drug discontinuation were 
lower in the delafloxacin group versus vancomycin/aztreonam 
(0.8% and 2.4% of patients, respectively).
Table 2. Demographics and Baseline Characteristics—Pooled Phase 3 Analysis Set
 Delafloxacin (N = 741) Vancomycin + Aztreonam (N = 751)
Age categories (year), n (%)
 ≤65 640 (86.4) 656 (87.4)
 >65 101 (13.6) 95 (12.6)
Sex, n (%)
 Male 459 (61.9) 483 (64.3)
 Female 282 (38.1) 268 (35.7)
Race, n (%)
 American Indian or Alaska Native 16 (2.2) 9 (1.2)
 Asian 12 (1.6) 16 (2.1)
 Black or African American 38 (5.1) 36 (4.8)
 Native Hawaiian or Other Pacific Islander 3 (0.4) 4 (0.5)
 White 636 (85.8) 656 (87.4)
 Other 36 (4.9) 30 (4.0)
Ethnicity, n (%)
 Hispanic or Latino 231 (31.2) 201 (26.8)
 Not Hispanic or Latino 510 (68.8) 550 (73.2)
Region, n (%)
 Asia 9 (1.2) 14 (1.9)
 Europe 225 (30.4) 228 (30.4)
 Latin America 46 (6.2) 43 (5.7)
 North America 461 (62.2) 466 (62.1)
Weight (kg)
 n 741 751
 Mean (SD) 85.5 (21.6) 85.8 (22.1)
 Median 82.6 83.0
 Min, Max 41.9, 198.5 43.8, 185.0
BMI ranges (kg/m2), n (%)
 BMI < 30 414 (55.9) 445 (59.3)
 BMI ≥ 30 327 (44.1) 306 (40.7)
Diabetes, n (%) 84 (11.3) 83 (11.1)
Baseline renal impairment, n (%) 121 (16.3) 121 (16.1)
Patients with history of hepatitis B or C, n (%) 216 (29.1) 217 (28.9)
Abbreviations: BMI, body mass index; SD, standard deviation.
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Treatment-related TEAEs with an incidence of ≥2% in either 
treatment arm of the pooled phase 3 data included gastroin-
testinal disorders comprising nausea at 6.1% versus 4.3%, and 
diarrhea at 6.1% and 2.0% for delafloxacin and vancomycin/
aztreonam, respectively. Gastrointestinal events were reported 
at comparable rates when delafloxacin was given by IV (17.3%, 
study 302) or by IV followed by oral doses (16.8%, study 303) [4, 
7]. Skin and subcutaneous tissue disorders were seen at 0.9% for 
delafloxacin and 4.7% for vancomycin/aztreonam.
The incidence of TEAEs between treatment groups was sim-
ilar regardless of age, gender, renal impairment, diabetic status, 
BMI, or hepatitis medical history (Figure 1).
Fluoroquinolone-related Adverse Events
There was no evidence of an increase in AESIs associated 
with FQs compared to the vancomycin/aztreonam group [8]. 
Numerically fewer patients had treatment-related FQ-related 
AEs in the delafloxacin group versus the comparator group, and 
Table 4. Overall Summary of Treatment-emergent Adverse Events—Pooled Phase 3
 







Total number of TEAEs 775 879
Patients with any TEAE 334 (45.1) 358 (47.7)
Patients with any related TEAE 164 (22.1) 196 (26.1)
Patients with any TEAE leading to premature study drug discontinuation 13 (1.8) 26 (3.5)
Patients with any related TEAE leading to premature study drug discontinuation 6 (0.8) 18 (2.4)
Patients with any TEAE of special interest, all cause 52 (7.0) 69 (9.2)
Patients with any serious TEAE 27 (3.6) 26 (3.5)
Patient with any related serious TEAE 2 (0.3) 4 (0.5)
Subjects with at least one related TEAE with incidence of ≥2%   
 Gastrointestinal disorders 81 (10.9) 45 (6.0)
 Nausea 45 (6.1) 32 (4.3)
 Diarrhea 45 (6.1) 15 (2.0)
Skin and subcutaneous tissue disorders (pruritus, urticaria, dermatitis, rash) 7 (0.9) 35 (4.7)
A TEAE was defined as an adverse event with (1) start date/time on or after the date/time of first study drug administration and prior to or on the date/time of last study medication admin-
istration + 28 days or (2) start date/time prior to the date/time of first study drug administration and worsening on or after the date/time of first study drug administration and prior to or on 
the date/time of last study medication administration + 28 days. Percentages are calculated as 100 × (n/N). The total number of TEAEs counts all TEAEs for patients. At each level of patient 
summarization, a patient with 1 or more reported events was counted only once, and the most severe reported event was used for the maximum severity. Related includes “possibly 
related,” “probably related,” “related,” and “definitely related.” Adverse events were coded using Medical Dictionary for Regulatory Activities Version 16.1.
Abbreviations: TEAE, treatment-emergent adverse event; VAN/AZ, vancomycin/aztreonam.






Duration of exposure (day)
 n 741 751
 Mean (SD) 6.8 (2.94) 6.6 (2.82)
 Median 6.0 6.0
 Min, Max 0.5, 14.0 0.5, 14.5
Duration of exposure, n (%)
 0.5 to < 4 days 48 (6.5) 54 (7.2)
 4 to < 6 days 301 (40.6) 291 (38.7)
 6 to < 8 days 180 (24.3) 211 (28.1)
 8 to < 10 days 88 (11.9) 89 (11.9)
 10 to < 14 days 104 (14.0) 88 (11.7)
 ≥14 days 20 (2.7) 18 (2.4)
Number of doses, n (%)
 1 to 10 doses 293 (39.5) 293 (39.0)
 11 to 28 doses 447 (60.3) 457 (60.9)
 >28 doses 1 (0.1) 1 (0.1)
One day of exposure is 2 doses. Abbreviation: SD, standard deviation.
aSummaries are for delafloxacin and vancomycin: Delafloxacin 300 mg intravenous (IV) / 450 mg oral Q12h; vancomycin 15 mg/kg (actual body weight) ± aztreonam 1–2 g IV q12h.
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there were no premature discontinuations from delafloxacin 
due to FQ-related AEs.
Hepatic events: Rates of all causality hepatic events (3.2% and 
3.4% for delafloxacin and vancomycin/aztreonam, respectively) 
and treatment-related hepatic events consisting of elevation of 
transaminases (2.2% and 2.7%, respectively) were similar be-
tween patients in the delafloxacin and comparator groups. 
These events were generally mild or moderate in severity, non-
serious, and no patients in either group met Hy’s Law. There 
were no discontinuations of treatment due to hepatic events.
Glucose events: Rates of treatment-related hyperglycemia 
and hypoglycemia were similar between patients in the dela-
floxacin and vancomycin/aztreonam groups (0.3% vs 0.1%) 
and (0.1% vs 0.3%) respectively. In study 302, glucose was 
carefully monitored over a period of 12 hours following IV 
delafloxacin doses in patients who were undergoing pharma-
cokinetic testing. No notable differences in blood glucose lev-
els were noted at any time point for either treatment group in 
that analysis [7].
Potential neuromuscular events: There were no cases of pe-
ripheral neuropathy or myopathy in the pooled phase 3 data 
and no cases that met the FDA definition of FQ-associated dis-
ability (FQAD) as defined by the FDA [9]. (Patients who were 
previously healthy, prescribed a FQ, and developed an adverse 
event in 2 or more of the following body systems: peripheral 
nervous system, neuropsychiatric, musculoskeletal, senses, 
cardiovascular, or skin. The events had to last for more than 
30 days after the FQ was discontinued and had a reported out-
come of disability.)
Clostridium difficile: One patient (0.1%) in the delafloxacin 
group had C. difficile infection compared with none in the van-
comycin/aztreonam group. The patient entered the study as a 
prior treatment failure with previous treatment with sulfameth-
oxazole/trimethoprim and clindamycin. The event of C. difficile 
infection was mild in severity and did not lead to treatment 
discontinuation.
Other notable class events: There were no patients in the 
delafloxacin group that had cases of QT prolongation or con-
vulsions. No patients in either treatment group had treat-
ment-related tendon disorder/rupture or phototoxicity.
CLINICAL LABORATORY EVALUATIONS
Changes in laboratory parameters were generally small and sim-
ilar between treatment groups, and mean values at end of treat-
ment remained within normal ranges. For relevant events that 
can be associated with a laboratory signal, such as hepatic events 
and dysglycemias, these laboratory changes generally occurred 
less frequently among delafloxacin patients than in the com-
parator group. In evaluation of laboratory testing, regardless 
of baseline values, only 8 patients in the delafloxacin treatment 
group reported alanine transaminase (ALT) >5 times the upper 
limit of normal (ULN) result at any time in the study, whereas 
13 patients in the vancomycin/aztreonam treatment groups re-
ported ALT >5 times ULN results at any time in the study. When 
such laboratory changes were seen, they typically were unlikely 
to be considered related to delafloxacin treatment, were con-
founded by other medical history/events/social circumstances, 
did not require treatment, and were reversible. (Table 5)
Figure 1. Treatment-emergent adverse events by subgroup. Abbreviations: BMI, body mass index; CrCl, creatinine clearance; TEAE, treatment-emergent adverse event.
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DISCUSSION
Despite some challenges with the class, persistent efforts have 
been made over the years to produce quinolones with superior 
antimicrobial properties enabled by the understanding of how 
molecular modification of the core quinolone structure affect the 
antimicrobial agent’s activity progressed rapidly [10, 11]. With 
the advent of newer agents, FQ prescribing increased 3-fold in 
the United States from 1995 to 2002 as they became the most 
commonly prescribed class of antibiotics to adults by 2002 [12].
With such widespread use and overuse came the recogni-
tion of a range of risks and AEs that were associated with the 
class [13]. In 2008, the FDA issued a black box warning for 
tendon rupture and most recently, in 2016, required changes 
to the label for all oral and injectable FQs, including a boxed 
warning related to disabling and potentially permanent side 
effects involving the tendons, muscles, joints, nerves, and cen-
tral nervous system [14].
As experience with the class has grown, AEs associated with 
the class have been well defined and have become a prospec-
tive part of the development process of more current FQs [1, 
15]. However, not all FQs have the same AE profile. SAR work 
has shown that different substitution on the core quinolone 
Table 5. Treatment-emergent Adverse Events of Special Interest (All Cause and Treatment-related)—Pooled Phase 3

















Subjects with at least one TEAE of special interest 52 (7.0) 69 (9.2) 25 (3.4) 43 (5.7)
Hepatic related events 23 (3.1) 30 (4.0) 16 (2.2) 20 (2.7)
 Increased ALT 14 (1.9) 14 (1.9) 10 (1.3) 10 (1.3)
 Increased AST 10 (1.3) 14 (1.9) 6 (0.8) 10 (1.3)
 Increased transaminases 3 (0.4) 5 (0.7)  3 (0.4) 2 (0.3)
 Increased hepatic enzyme 2 (0.3) 2 (0.3) 1 (0.1) 2 (0.3)
 Liver function test abnormal 0 2 (0.3) 0 2 (0.3)
 Hypertransaminasaemia 2 (0.3) 1 (0.1) 1 (0.1) 1 (0.1)
 Increased gamma-glutamyltransferase 1 (0.1) 1 (0.1) 0 0
 Hepatic cirrhosis 0 1 (0.1) 0 0
Potential myopathy 15 (2.0) 34 (4.5) 7 (0.9) 20 (2.7)
 Increased blood creatinine Phosphokinase 8 (1.1) 15 (2.0) 3 (0.4) 7 (0.9)
 Increased blood creatinine 2 (0.3) 4 (0.5) 1 (0.1) 4 (0.5)
 Myalgia 1 (0.1) 2 (0.3) 0 1 (0.1)
 Renal impairment 2 (0.3) 1 (0.1) 2 (0.3) 0
 Renal failure – acute 1 (0.1) 7 (0.9) 1 (0.1) 3 (0.4)
 Musculoskeletal pain 1 (0.1) 2 (0.3) 0 1 (0.1)
 Renal failure 0 3 (0.4) 0 3 (0.4)
 Decreased creatinine renal clearance 0 1 (0.1) 0 1 (0.1)
Hyperglycemia 6 (0.8) 4 (0.5) 2 (0.3) 1 (0.1)
 Hyperglycemia 2 (0.3) 2 (0.3) 2 (0.3) 1 (0.1)
 Diabetes mellitus 3 (0.4) 1 (0.1) 0 0
 Type 2 diabetes mellitus 1 (0.1) 1 (0.1) 0 0
Potential peripheral neuropathy 4 (0.5) 3 (0.4) 1 (0.1) 2 (0.3)
 Paraesthesia 4 (0.5) 1 (0.1) 1 (0.1) 1 (0.1)
 Hypoaesthesia 1 (0.1) 1 (0.1) 0 1 (0.1)
 Neuropathy peripheral 0 1 (0.1) 0 0
Potential QT prolongation 2 (0.3) 1 (0.1) 0 1 (0.1)
 Syncope 2 (0.3) 0 0 0
 Loss of consciousness 0 1 (0.1) 0 1 (0.1)
Potential tendon disorder 3 (0.4) 1 (0.1) 0 0
 Tendonitis 3 (0.4) 0 0 0
 Trigger finger 0 1 (0.1) 0 0
Hypoglycemia 2 (0.3) 3 (0.4) 1 (0.1) 2 (0.3)
C. difficile infection 1 (0.1) 0 1 (0.1) 0
Convulsions 0 1 (0.1) 0 1 (0.1)
Potential phototoxicity 0 0 0 0
Abbreviations: AESI, adverse events of special interest; ALT, alanine transaminase; AST, aspartate transaminase; TEAE, treatment-emergent adverse event; VAN/AZ, vancomycin/aztreonam.
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molecule results in difference among the class not only in spec-
trum of activity but also side effects [1, 16]. For example, the 
introduction of fluorine or chlorine into the molecule, which 
otherwise provided beneficial effects, was associated with 
phototoxicity. It was later found that the severity of a side ef-
fect might be influenced by moieties attached to other sites on 
the FQ core structure. For example, the moiety at position 1 
appears to influence the phototoxic potential of the 8-halogen 
FQs [16, 17].
Delafloxacin is an IV/oral FQ approved in the United States 
for the treatment of adults with ABSSSI and has unique struc-
tural attributes that may be associated with a differentiated 
AE profile compared to other FQs. Although the delafloxacin 
label carries the FDA class boxed warning, other FQ-associated 
events are not found in the warnings/precautions section. Those 
absent from the label include peripheral neuropathy, CNS 
effects, and myasthenia gravis, QT/torsades, photosensitivity, 
hepatotoxicity/hepatitis, dysglycemias, and multiple classes of 
drug interactions [18]. Regardless, as with all drugs including 
antibiotics, it is sensible to continue to assess and further char-
acterize delafloxacin’s safety profile and the pooling of phase 3 
safety data for delafloxacin in ABSSSI provides an opportunity 
to do so. This analysis compared the incidence of AEs between 
delafloxacin and vancomycin/aztreonam across two phase 3 
registrational ABSSSI studies.
Any related TEAEs were seen in the pooled delafloxacin 
group versus comparator group (22.1% vs 26.1%, respectively) 
and delafloxacin had a low rate of discontinuations due to treat-
ment-related AEs (0.8%) compared to vancomycin/aztreonam 
(2.4%). The most common TEAE reported for delafloxacin have 
been diarrhea and nausea, both at reported rates of 6.1% and 
were mild to moderate in nature. Oral delafloxacin doses were 
not associated with an increase in overall gastrointestinal events 
in the comparison of these 2 pivotal trials (17.3%, study 302 
vs 16.8%, study 303). Serious AEs occurred at similar rates in 
patients treated with delafloxacin versus vancomycin/aztreo-
nam, suggesting a favorable risk-benefit ratio for delafloxacin 
in the treatment of ABSSSIs as vancomycin is widely used in 
this indication. There has been only 1 death in patients with 
delafloxacin in the phase 3 studies, which was considered unre-
lated to delafloxacin.
FQs have been associated with a number of well-described 
risks. The development of new FQs can thus include prospec-
tive evaluation and monitoring for these potential class-related 
AESIs. In these 2 pooled studies, AE reports potentially related 
to the AESIs were identified by medical review and use of SMQS 
where possible. SMQs are validated, standard sets of MedDRA 
terms used to support signal detection, which are used to assess 
and evaluate a variety of safety topics of regulatory interest [19]. 
The SMQs provide a framework for broad consideration of mul-
tiple AE terms that could potentially be associated with a med-
ical event of interest. For example, the SMQ for potential QT 
prolongation includes events as specific as Torsade de pointes as 
well as events as general as syncope. This conservative approach 
allows a view of many events across body systems, in order to 
evaluate signals that may be otherwise difficult to assess. Even 
with the conservative assessment encompassing any AE that 
might even remotely be considered, the AESIs in the phase 3 clin-
ical studies associated with FQ use were less frequently seen in 
the delafloxacin group than in the vancomycin/aztreonam group. 
This safety analysis indicates that delafloxacin does not appear to 
have an increased rate of AESIs that have been seen with other 
FQs. A more detailed analysis is published elsewhere [8].
When selecting an appropriate antibiotic for patients with 
ABSSSI, the prescribing physician has to consider a number of 
issues including potential pathogens, patient’s comorbidities, 
concomitant medications, and challenges for drug administra-
tion. Pooling of the phase 3 data allows a more robust analysis 
of subsets of patients that may offer further insight into various 
patient types. Fixed dose delafloxacin has comparable safety 
outcomes regardless of age, sex, renal impairment, diabetic sta-
tus, BMI, or hepatitis medical history, does not require ther-
apeutic drug monitoring, and does not require weight-based 
dosing.
Changes in laboratory parameters were generally small and 
similar between treatment groups, and mean values at end of 
treatment remained within normal ranges. For AESIs that can 
be associated with a laboratory signal, such as hepatic events 
and dysglycemias, these laboratory changes generally occurred 
less frequently among delafloxacin patients than in the vanco-
mycin/aztreonam group. When such laboratory changes were 
seen, they typically were unlikely to be considered related to 
delafloxacin treatment, were confounded by other medical his-
tory/events/social circumstances, did not require treatment, 
and were reversible.
Patients that may require an antibiotic with a profile like 
delafloxacin often have comorbidities that are associated with 
polypharmacy, and so potential drug-drug-interaction is an 
important consideration. No known drug interactions were 
observed in the clinical studies. In vitro studies conducted with 
human liver microsomes showed that delafloxacin is not an in-
hibitor of CYP1A2 nor any of the other isozymes (CYP2A6, 
CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or 
CYP3A4/5). However, delafloxacin is a mild inducer of CYP3A 
in cultures of human hepatocytes. A study using midazolam as 
an established CYP3A probe showed no clinically meaningful 
induction of CYP3a by delafloxacin [20].
There are limitations to this analysis. The database is robust 
but still limited in terms of the number of patients and duration. 
The 14-day duration of treatment in the phase 3 trials is the 
longest duration of dosing in a clinical trial to date. Further, the 
comparator was not an FQ, and so a dependence on a compar-
ison of the AESIs within the basal population rate is necessary. 
Characterizing the risk of some AESIs in the general population 
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is difficult [2]; however, delafloxacin rates of any TEAEs as 
well as related TEAEs were lower than those of vancomycin/
aztreonam.
The key with all medical treatments is to balance the good 
and helpful with the risk of potential harm from side effects. If 
a patient has an invasive serious bacterial infection, antibiotics 
are potentially life-saving. Available data show delafloxacin is 
well tolerated in both IV and oral formulation for the treatment 
of ABSSSI and does not appear to be associated with increased 
risk of AESIs associated with other FQs. It remains important to 
monitor for potential AEs that have been observed with other 
FQs.
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